24/7 Wall St. on MSN
Triple-leveraged biotech ETF doubles as regulatory winds shift in 2026
Quick Read Direxion Biotech Bull 3X (LABU) doubled over the past year by delivering three times the daily biotech index ...
Zacks Investment Research on MSN
Is Invesco Pharmaceuticals ETF (PJP) a strong ETF right now?
The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer ...
The VanEck Pharmaceutical ETF provides diversified exposure to the world's largest pharmaceutical companies, focusing on 'big pharma' through a cap-weighted index. PPH tracks the MVIS US Listed ...
24/7 Wall St. on MSN
Biotech Could Be One of 2026’s Biggest Winners, and This ETF Is Perfectly Positioned
Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...
VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings ...
Zacks.com on MSN
Here's Why Biotech ETFs Are Rallying Hard
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of ...
A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...
The current generation of deals, which is likely to involve AbbVie (NYSE: ABBV), Merck & Co Inc (NYSE: MRK), Bristol-Myers Squibb Co (NYSE: BMY), and Gilead Sciences Inc (NYSE: GILD), is focused on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results